Prevention of coronary obstruction in patients at risk undergoing transcatheter aortic valve implantation: the Hamburg BASILICA experience

Dirk Westermann1,2 · Sebastian Ludwig1,2 · Daniel Kalbacher1,2 · Clemens Spink3 · Matthias Linder1 · Oliver D. Bhadra4 · Julius Nikorowitsch1 · Lara Waldschmidt1 · Till Demal4 · Lisa Voigtländer1,2 · Andreas Schaefer4 · Moritz Seiffert1,2 · Simon Pecha2,4 · Niklas Schofer1 · Adam B. Greenbaum5 · Hermann Reichenspurner2,4 · Stefan Blankenberg1,2 · Lenard Conradi2,4 · Johannes Schirmer4

Received: 30 March 2021 / Accepted: 26 May 2021 / Published online: 22 June 2021 © The Author(s) 2021, corrected publication 2021

Abstract
Objectives This study aimed to assess the clinical outcome of the bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary obstruction (BASILICA) technique in a single-center patient cohort considered at high or prohibitive risk of transcatheter aortic valve implantation (TAVI)-induced coronary obstruction.

Methods Between October 2019 and January 2021, a total of 15 consecutive patients (age 81.0 [78.1, 84.4] years; 53.3% female; EuroSCORE II 10.6 [6.3, 14.8] %) underwent BASILICA procedure prior to TAVI at our institution. Indications for TAVI were degeneration of stented (n = 12, 80.0%) or stentless (n = 1, 6.7%) bioprosthetic aortic valves, or calcific stenosis of native aortic valves (n = 2, 13.3%), respectively. Individual risk of TAVI-induced coronary obstruction was assessed by pre-procedural computed tomography analysis. Procedural and 30-day outcomes were documented in accordance with Valve Academic Research Consortium (VARC)-2 criteria.

Results BASILICA was attempted for single left coronary cusp in 12 patients (80.0%), for single right coronary cusp in 2 patients (13.3%), and for both cusps in 1 patient (6.7%), respectively. The procedure was feasible in 13 patients (86.7%) resulting in effective prevention of coronary obstruction, whilst TAVI was performed without prior successful bioprosthetic leaflet laceration in two patients (13.3%). In one of these patients (6.7%), additional chimney stenting immediately after TAVI was performed. No all-cause deaths or strokes were documented after 30 days.

Conclusion The BASILICA technique appears to be a feasible, safe and effective concept to avoid iatrogenic coronary artery obstruction during TAVI in both native and bioprosthetic valves of patients at high or prohibitive risk.

ClinicalTrials.gov Identifier: NCT04227002 (Hamburg AoRtic Valve cOhoRt).

Keywords Transcatheter aortic valve implantation · Coronary obstruction · BASILICA
**Introduction**

Over the past decade, transcatheter aortic valve implantation (TAVI) has evolved to routine therapy for patients suffering from symptomatic aortic valve disease [1]. However, acute coronary obstruction during TAVI, either directly or indirectly by sequestering the sinus of Valsalva (SOV) at the sinotubular junction (STJ), is a rare but potentially devastating complication. Occurring in < 1% of TAVI procedures, high mortality rates of up to 50% within 30 days have been reported leading to increasing efforts to anticipate and prevent this life-threatening complication [2–4]. Risk of coronary obstruction is particularly elevated in patients with prior surgical aortic valve replacement (SAVR) undergoing valve-in-valve (ViV) TAVI, with a four- to sixfold higher incidence compared to TAVI for native aortic valve disease [2, 4, 5]. Pre-procedural contrast-enhanced multislice computed tomography (MSCT) imaging with virtual transcatheter heart valve (THV) implantation plays a pivotal role in identifying these patients at high or prohibitive risk [2, 6].

Until recently, protective management in patients with increased risk of coronary obstruction during TAVI included upfront coronary wire advancement in the threatened coronary artery with the option to perform immediate chimney stenting [7]. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) technique is an alternative and promising endovascular electrosurgical method to avoid fatal coronary occlusion [8]. Initial results have demonstrated feasibility and safety of this procedure [9, 10]. With this study, we present a single-center experience of 15 patients with either native aortic stenosis (AS) or degenerated surgical bioprostheses, all at high risk of coronary obstruction after native valve TAVI or ViV TAVI, undergoing intentional leaflet laceration with the BASILICA technique.

**Methods**

**Study population and data acquisition**

Since its initiation at University Heart and Vascular Center Hamburg in 2019, the prospective Hamburg AorRtic valve cOhoRt (HARbOR) Registry (NCT04227002) has included 535 patients with aortic valve disease. Of these, 449 patients were treated with TAVI for symptomatic native aortic valvular disease, whilst 42 patients underwent ViV TAVI for degenerated bioprosthetic aortic valves. Patients treated medically or with (Redo-)SAVR (N = 44) were excluded from this study. Between October 2019 and January 2021, a total of 15 patients at high or prohibitive risk of coronary obstruction were identified as candidates for the BASILICA procedure, of whom 2 patients (13.3%) received native valve TAVI and 13 patients (86.7%) underwent ViV TAVI. A study flowchart is given in Fig. 1. Clinical endpoints were adjudicated according to current Valve Academic Research Consortium (VARC)-2 criteria after 30 days. Allocation of patients to TAVI followed the consensus of the local dedicated interdisciplinary heart team based on established criteria. All patients provided informed consent to the procedure and data acquisition. The study was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki.

![Fig. 1 Study flowchart. AR aortic regurgitation, AS aortic stenosis, BASILICA bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction, CO coronary obstruction, SAVR surgical aortic valve replacement, SHV surgical heart valve, TAVI transcatheter aortic valve implantation, THV transcatheter heart valve, ViV valve-in-valve](image-url)
Echocardiographic measurements

Transthoracic and transesophageal echocardiography at baseline were performed in all patients. Severity of AS and grade of bioprosthesis valve degeneration were assessed according to current ESC/EACTS guidelines for the management of valvular heart disease [11]. Evaluation of THV function at discharge was assessed by transthoracic echocardiography.

Computed tomography analysis

All patients underwent pre-procedural contrast-enhanced MSCT. Three-dimensional reconstruction of the aortic valve and risk assessment for coronary obstruction were performed using a dedicated software (3mensio Structural Heart V9.1, Pie Medical Imaging, Maastricht, The Netherlands). The annular plane was defined using a 3-point technique [12]. Valve-to-coronary (VTC) and valve-to-sinotubular junction (VTSTJ) distances were measured following virtual implantation of the THV planned for each individual procedure, based on a previously published method [13]. Coronary height [left coronary artery (LCA); right coronary artery (RCA)] and STJ height were measured orthogonally from the pre-defined aortic valve annulus (or surgical prosthesis). SOV diameters were assessed separately for each cusp, while STJ diameter was derived from STJ perimeter.

Concept of Deficient and Sequestered Sinus

Indication for BASILICA was assessed according to the concept of *Deficient* and *Sequestered Sinus*, as described

![Fig. 2 Deficient Sinus. 3mensio Structural Heart V9.1, Pie Medical Imaging, Maastricht, Netherlands. A Deficient Sinus (pre-procedural CT). Deficient Sinus is defined by low coronary height and narrow sinus of Valsalva. Measurement (3.1 mm) indicates low left coronary artery height. Surgical valve leaflets have been drawn retrospectively. B Coronary obstruction in a patient with Deficient Sinus (pre-procedural CT with a virtually implanted THV (Evolut R, Medtronic)). Following THV implantation, the surgical valve leaflet directly obstructs the complete sinus of Valsalva, including the LCA, inhibiting coronary blood flow. C Valve-to-coronary (VTC) distance (3D CT reconstruction). CT computed tomography, LCA left coronary artery, THV transcatheter heart valve, VTC valve-to-coronary distance*](image)
by Lederman et al. [6], leading to high or prohibitive risk of either direct or indirect coronary obstruction, respectively. Patients with Deficient Sinus (Fig. 2) are characterized by small SOV diameter and low coronary artery height. If left untreated, implantation of a THV may result in direct coronary obstruction by a leaflet due to an obliterated or effaced SOV in these patients. The VTC distance is considered the main determinant for risk of coronary obstruction in patients with Deficient Sinus. In patients with Sequestered Sinus (Fig. 3), multiple factors may result in high risk of indirect coronary obstruction. Depending on STJ height, STJ diameter and outer THV frame diameter, blood flow into the SOV may be impaired by leaflet obstruction on the height of STJ. Risk of coronary obstruction in patients with Sequestered Sinus is assessed by measurement of VTSTJ distance [6].

**BASILICA procedure**

The BASILICA procedure was performed under general anesthesia immediately prior to TAVI via bilateral femoral access. Correct positions and orientations of catheters and guidewires were checked and guided using transesophageal echocardiography and fluoroscopy using valvular front- and side-views pre-determined by MSCT before the procedure. Procedural setup routinely included insertion of a cerebral embolic protection device (Sentinel, Boston Scientific, Marlborough, MA, USA). The BASILICA technique has been described in detail elsewhere [6, 8, 9, 14]. In brief, two guiding catheters are positioned on either side of the aortic leaflet at risk, with a traversal 0.014-in. guidewire (Astato XS 20 300 cm, Asahi Intecc, Aichi,
Japan) insulated in a micro-guide catheter (FineCross MG, Terumo, Tokyo, Japan) in the aortic root, and a snare (OneSnare, Merit Medical, South Jordan, UT, USA) in the left ventricular outflow tract (Fig. 4A). The electrified guidewire is directed through the base of the target leaflet into the snare (Fig. 4B). The guidewire is then externalized by snare retrieval forming a loop through the penetrated leaflet between the two guiding catheters (Fig. 4C). Intentional laceration of the target leaflet is achieved by focally applied electricity while gently pulling both free ends of the guidewire. Before splitting the leaflet, the guidewire is manually denuded of PTFE insulation at the mid-shaft to confine electrical contact with leaflet tissue, and kinked to form a *flying V* configuration. A standard electrosurgical generator (Covidien Force FX, Medtronic, Minneapolis, MN, USA) was used for electrical current supply. Implantation of the THV in the native or bioprosthetic aortic valve, respectively, was performed immediately afterwards as a standardized approach (Fig. 4D) [6, 8, 9, 14].

Statistical analysis

Data are presented as absolute numbers and percentages for categorical variables, and median values (25th percentile, 75th percentile) for continuous variables.

Results

Baseline characteristics

Patient baseline characteristics are depicted in Table 1. The study population (*n* = 15) was nearly equally distributed regarding gender (female: 53.3%) and characterized by an elderly patient cohort (81.0 [78.1, 84.4] years), with elevated
rates of atrial fibrillation (53.3%), coexisting coronary artery disease (46.7%) and chronic kidney disease (60.0%) resulting in intermediate to high surgical risk according to established risk scores (EuroSCORE II: 10.6 [6.3, 14.8]%; STS PROM: 3.4 [2.4, 7.2]%).

13 out of 15 patients (86.7%) had a history of previous bioprosthetic SAVR, three of them (23.1%) had undergone concomitant coronary artery bypass graft surgery. Surgical bioprostheses were stented prostheses with either internally mounted (Hancock II, Medtronic, \( n = 4, 30.8\)) or externally mounted leaflets (Mitroflow, Sorin, \( n = 5, 38.5\); Trifecta, St. Jude Medical/Abbott, \( n = 3, 23.1\)), and one stentless prosthesis (Freedom Solo, Sorin, 7.7%). Morphologies of bioprosthetic valve degeneration were severe stenosis in 5 patients (33.3%), severe regurgitation in 6 patients (40.0%) and combined stenosis/regurgitation in 2 patients (13.3%). Furthermore, 2 patients (13.3%) with severe native valve AS were treated. Detailed pre-procedural data are presented in Table 2.

### Indication for BASILICA

MSCT-based parameters utilized for risk assessment of coronary obstruction by left coronary cusp (LCC) and/or right coronary cusp (RCC) are summarized in Table 3. Out of 8 patients (53.3%) presenting with Deficient Sinus, high risk for LCC obstruction was found in 6 patients (40.0%) with low LCA height (5.2 [3.7, 9.8] mm) and small LCC SOV

### Table 1 Patient baseline characteristics

| Characteristics                              | \( n = 15 \) |
|----------------------------------------------|--------------|
| Age (years)                                  | 81.0 (78.1, 84.4) |
| Female gender [\( n (\%) \)]                | 8 (53.3)     |
| Body mass index (kg/m\(^2\))                | 26.0 (23.1, 28.2) |
| EuroSCORE II (%)                            | 10.6 (6.3, 14.8) |
| STS PROM (%)                                 | 3.4 (2.4, 7.2) |
| NYHA functional class III or IV [\( n (\%) \)] | 12 (80.0)     |
| Atrial fibrillation [\( n (\%) \)]          | 8 (53.3)     |
| Prior stroke [\( n (\%) \)]                 | 1 (6.7)      |
| Peripheral artery disease [\( n (\%) \)]    | 3 (20.0)     |
| Chronic kidney disease (GFR < 50 mL/min) [\( n (\%) \)] | 9 (60.0)     |
| Diabetes [\( n (\%) \)]                    | 2 (13.3)     |
| COPD [\( n (\%) \)]                         | 3 (20.0)     |
| Prior SAVR [\( n (\%) \)]                  | 13 (86.7)    |
| Coronary artery disease [\( n (\%) \)]      | 7 (46.7)     |
| Prior myocardial infarction [\( n (\%) \)]  | 2 (13.3)     |
| Prior CAVG [\( n (\%) \)]                  | 3 (20.0)     |
| Prior PCI [\( n (\%) \)]                   | 4 (26.7)     |

Values are \( n (\%) \) or median (interquartile range)

\( CABG \) coronary artery bypass graft, \( COPD \) chronic obstructive pulmonary disease, \( GFR \) glomerular filtration rate, \( NYHA \) New York Heart Association, \( PCI \) percutaneous coronary intervention, \( SAVR \) surgical aortic valve replacement, \( STS PROM \) Society of Thoracic Surgeons predicted risk of mortality

### Table 2 Pre-procedural data

| Types of surgical bioprostheses [\( n = 13 \)]                  |
|---------------------------------------------------------------|
| Stented prostheses, internally mounted leaflets               |
| Hancock II, Medtronic                                        | 4 (30.8)     |
| Stented prostheses, externally mounted leaflets               |
| Mitroflow, Sorin                                             | 5 (38.5)     |
| Trifecta, St. Jude Medical/Abbott                             | 3 (23.1)     |
| Stentless prosthesis                                         |
| Freedom Solo, Sorin                                          | 1 (7.7)      |

| Morphology of aortic valve degeneration [\( n = 15 \)]          |
|---------------------------------------------------------------|
| Native valve aortic stenosis                                  | 2 (13.3)     |
| Surgical bioprostheses                                        |
| Aortic stenosis                                               | 5 (33.3)     |
| Aortic regurgitation                                          | 6 (40.0)     |
| Combined stenosis/regurgitation                               | 2 (13.3)     |

| Echocardiographic parameters [\( n = 15 \)]                    |
|---------------------------------------------------------------|
| Mean AV gradient (mmHg)                                       | 28.0 (19.0, 38.0) |
| Effective orifice area (cm\(^2\))                             | 0.9 (0.8, 1.2)   |
| Mitral regurgitation ≥ moderate                               | 4 (26.7)       |
| Tricuspid regurgitation ≥ moderate                            | 4 (26.7)       |
| LVEF (%)                                                      | 55.0 (44.0, 60.0) |

Values are \( n (\%) \) or median (interquartile range)

\( AV \) aortic valve, \( LVEF \) left ventricular ejection fraction

### Table 3 MSCT-based risk assessment of coronary obstruction

| Deficient Sinus [\( n = 8 \)]                                 |
|---------------------------------------------------------------|
| LCC \( n = 6 \)                                               |
| LCA height (mm)                                               | 5.2 (3.7, 9.8) |
| SOV diameter (LCC) (mm)                                       | 27.3 (26.3, 29.3) |
| VTC (LCA) (mm)                                                | 2.9 (2.2, 3.4) |
| RCC \( n = 3 \)                                               |
| RCA height (mm)                                               | 10.1 (9.0, 10.2) |
| SOV diameter (RCC) (mm)                                       | 25.8 (24.2, 26.6) |
| VTC (RCA) (mm)                                                | 2.8 (2.5, 2.9) |

| Sequestered Sinus [\( n = 7 \)]                              |
|---------------------------------------------------------------|
| LCC \( n = 7 \)                                               |
| STJ height (mm)                                               | 16.6 (14.8, 18.3) |
| STJ diameter (mm)                                             | 28.3 (26.5, 29.4) |
| VTSTJ (mm)                                                    | 2.5 (0.6, 2.9) |
| VTSTJ = 0 mm [\( n (\%) \)]                                  | 2 (28.6)       |

Values are \( n (\%) \) or median (interquartile range)

\( LCA \) left coronary artery, \( LCC \) left coronary cusp, \( RCC \) right coronary artery, \( SOV \) sinus of Valsalva, \( STJ \) sinotubular junction, \( VTC \) valve-to-coronary distance, \( VTSTJ \) valve-to-sinotubular junction distance

\(^a\)In one patient, BASILICA was performed for both LCC and RCC
diameter (27.3 [26.3, 29.3] mm) resulting in low VTC distance to LCA (2.9 [2.2, 3.4] mm). In three patients (20.0%) risk for RCC obstruction was identified, with low RCA height (10.1 [9.0, 10.2] mm), small RCC SOV diameter (25.8 [24.2, 26.6] mm) and low VTC distance to RCA (2.8 [2.5, 2.9] mm). Of these, 1 patient (6.7%) was at risk for obstruction of both coronary ostia. Consequently, BASILICA was attempted for single LCC in 5 patients (33.3%), for single RCC in 2 patients (13.3%), and for both cusps in 1 patient (6.7%), respectively.

Further, 7 patients (46.7%) were identified with Sequenced Sinus, all at high risk for LCC obstruction, characterized by low STJ height (16.6 [14.8, 18.3] mm) in combination with low STJ diameter (28.3 [26.5, 29.4] mm) and resulting in low VTSTJ distance (2.6 [2.5, 3.1] mm). Therefore, BASILICA was attempted for single LCC in these patients. Overall, BASILICA was intended for 16 leaflets (LCC: n = 13, 81.3%; RCC: n = 3, 18.8%) in 15 patients.

### Table 4 Procedural data

| Characteristics                  | Values          |
|----------------------------------|-----------------|
| Target leaflet for BASILICA      |                 |
| LCC                              | 12 (80.0)       |
| RCC                              | 2 (13.3)        |
| Both cusps                       | 1 (6.7)         |
| Cerebral protection device       | 15 (100)        |
| Transfemoral access for TAVI     | 15 (100)        |
| Balloon pre-dilatation           | 0 (0)           |
| Balloon post-dilatation          | 5 (33.3)        |
| Bioprosthetic valve fracture     | 1 (6.7)         |
| Total procedure time (min)       | 160 (146, 178)  |
| Fluoroscopy time (min)           | 52 (45, 56)     |
| Contrast agent volume (mL)       | 281 (172, 352)  |
| THV prostheses                   |                 |
| Self-expanding THV               |                 |
| CoreValve Evolut R, Medtronic    | 14 (93.3)       |
| 23 mm/26 mm                      | 5 (33.3)/9 (60.0) |
| Balloon-expandable THV           |                 |
| Sapien 3 Ultra 26 mm, Edwards Lifesciences | 1 (6.7) |

Values are n (%) or median (interquartile range)

BASILICA bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction, LCC left coronary cusp, RCC right coronary cusp, TAVI transcatheter aortic valve implantation, THV transcatheter heart valve

Fig. 5 BASILICA failure. A Impenetrable calcified leaflet (Sorin Mitroflow surgical valve). B Wire-interference with a THV in mitral position (Sapien-in-MAC), Sorin Mitroflow aortic valve, pre-TAVI three-dimensional CT reconstruction. C pre-TAVI CT (see B). BASILICA bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction, CT computed tomography, MAC mitral annulus calcification, TAVI transcatheter aortic valve implantation, THV transcatheter heart valve
of obstruction on the height of STJ (Fig. 6) and the other removed due to sufficient coronary flow. Hemodynamic instability did not occur in any procedure during the BASILICA maneuver.

THV implantation immediately after the BASILICA procedure was successful in all 15 patients. Transfemoral access for TAVI was chosen in all cases. In 14 patients (93.3%), a self-expanding CoreValve Evolut R (Medtronic) was implanted. In 1 patient (6.7%), a balloon-expandable Sapien 3 Ultra THV (Edwards Lifesciences) was used. Intentional bioprosthetic valve fracture by high-pressure balloon inflation following TAVI was performed in one case (6.7%) due to increased transvalvular gradient post-implant. Leaflet laceration was confirmed by transesophageal echocardiography during the procedure (Fig. 7A) and by post-TAVI MSCT (Fig. 7B, C) in selected patients.

Adjudicated VARC-2 efficacy and safety endpoints are depicted in Table 5. No all-cause mortality, myocardial infarction, stroke or acute kidney injury was documented until 30 days. There were no cases requiring new permanent pacemaker implantation or repeat procedure due to valve-related dysfunction. A major access site complication with
resultant major bleeding on postoperative day one occurred in 1 patient (6.7%).

Echocardiography at discharge revealed sufficient valvular function in all patients. Mean transprosthetic gradient was 9.0 (5.5, 14.0) mmHg. In 2 patients (13.3%) increased mean aortic valve gradient > 20 mmHg was measured at discharge echocardiography. No paravalvular leakage greater than trace was observed.

No statistically significant differences in procedure time, dose area product or contrast agent were found comparing the first half of patients successfully treated with a single leaflet laceration (N = 11) to the second half. However, procedure time (156.6 ± 12.5 min vs. 149.2 ± 25.6 min, p = 0.55) and dose area product (17,514.8 ± 6775.7 cGy cm² vs. 13,798.2 ± 4248.2 cGy cm², p = 0.35) numerically decreased, while usage of contrast agent numerically increased over time (192.6 ± 87.8 mL vs. 234.2 ± 111.0 mL, p = 0.57).

**Discussion**

We herein present our single-center experience with the BASILICA technique to facilitate TAVI procedures in patients at high risk of coronary obstruction. While being safe and feasible future trials need to evaluate detailed inclusion criteria prospectively.

**Risk assessment of iatrogenic coronary obstruction**

Recently, several studies have assessed the incidence and predictors of coronary obstruction in patients undergoing native valve TAVI or ViV TAVI for degenerated surgical bioprostheses. The incidence of coronary obstruction in patients treated for native AS appears to be low, with low coronary height and small SOV diameters, defined as Deficient Sinus, causing direct occlusion of a coronary artery by native leaflet [4, 15, 16]. A coronary height cut-off of 12 mm has been established as an indicator of high risk for direct coronary obstruction [4, 17]. In a large multicenter registry of 6688 patients, who underwent TAVI or ViV TAVI, rates of coronary obstruction were 0.62% and 2.48% for TAVI in native AS and ViV-TAVI, respectively, indicating a higher
risk of coronary obstruction in patients with prior SAVR [4]. Indeed, ViV TAVI was identified as an independent predictor of coronary obstruction in this cohort [4].

In patients undergoing ViV TAVI, two mechanisms potentially causing coronary obstruction have to be distinguished. The primary mechanism is direct occlusion of a coronary artery by a prosthetic leaflet in patients with Deficient Sinus [17]. A second mechanism is premised on the extension of bioprosthetic structures to the STJ, in particular in the presence of low STJ height and small STJ diameter, resulting in indirect coronary obstruction by the creation of a covered cylinder after THV implantation (Sequestered Sinus) [17]. Besides these anatomical risk determinants, bioprosthetic valve characteristics like supra-annular leaflet position, high leaflet profile and externally mounted leaflets in stented prostheses are considered for risk assessment before ViV TAVI [18]. In an analysis of 1612 patients enrolled in the Valve-in-Valve International Data (VIVID) Registry, Ribeiro et al. observed significantly higher rates of coronary obstruction in patients with stentless bioprostheses (3.7%) and stented prostheses with externally mounted leaflets (6.4%) compared to those with internally mounted leaflets (0.7%) [2]. In addition, VTC distance was identified as a valid and independent MSCT-derived predictor of coronary obstruction [2]. Recently, Tang et al. proposed an algorithm for risk assessment of coronary obstruction before ViV TAVI based on VTC and VTSTJ cut-off values of <4 mm and <2.5–3.5 mm, respectively. The authors also introduced the VIVID classification, which specifies aortic root anatomies based on the concept of Deficient and Sequestered Sinus [19].

The above findings are supported by our own results in this single-center study, with most patients identified at high risk of coronary obstruction having a history of prior SAVR, and only two patients presenting with severe native AS. Moreover, more than half of the patients scheduled for ViV TAVI had either stented surgical bioprostheses with externally mounted leaflets or a stentless prosthesis. High risk of coronary obstruction in the present patient cohort was confirmed by low VTC and VTSTJ distances in the groups of Deficient and Sequestered Sinus, respectively. Considering all subjects, the LCA was identified as coronary artery at risk in the vast majority of cases, while the RCA was considered vulnerable in only two patients. This is consistent with findings from the above-mentioned multicenter registries, with LCA obstruction rates of 88.6% and 72.2%, respectively, referred to all coronary obstruction cases in native valve TAVI or ViV TAVI procedures [2, 4].

Chimney stenting represents an established bailout strategy for iatrogenic coronary occlusion after TAVI. By upfront positioning of a coronary guidewire, balloon or undeployed stent in the coronary artery at risk, a stent can be deployed between the displaced leaflets and the aortic wall in case of compromised coronary blood flow [7]. However, mechanical stent compression, restenosis and late stent thrombosis have to be taken into account when using this technique. Moreover, coronary re-access after chimney stenting is extremely challenging [7].

**BASILICA technique**

The concept of the BASILICA procedure for the prevention of coronary obstruction during TAVI was first described in 2018 by Khan et al. in a series of compassionate use cases [8]. Since then, feasibility, efficacy and safety of this novel technique have been demonstrated by few studies [9, 10]. One large series from a multicenter registry comprised 30 patients, in whom BASILICA was intended during native valve TAVI and ViV TAVI. Successful traversal and laceration were achieved in 93.3% of these cases with the absence of procedural coronary obstruction or procedural mortality. Rates of cardiovascular mortality (3.3%), disabling stroke (3.3%) and life-threatening bleeding (6.6%) were low, with an elevated rate of major vascular complications (20.0%). Recently, the largest retrospective study to date was published including 214 patients from 25 centers. Again, cardiovascular mortality was low with 2.8% and stroke risk being 2.8% [20]. The results of the present study are in line with these data demonstrating solid feasibility (successful in 92.3% of LCC and 66.7% of RCC intents) and safety of the procedure without procedural mortality or valve-related dysfunction requiring repeat procedure. Rates of vascular or hemorrhagic complications were low in this single-center series. Stroke or other neurological deficits were not observed in this small patient cohort. One might expect increased risk of calcific embolization during BASILICA maneuver due to prolonged catheter manipulation along the target cusp and leaflet laceration debris. Routine insertion of a cerebral embolic protection device in all subjects potentially may have accounted for the absence of neurological events. In contrast, Khan et al. described three cases of stroke in 30 subjects enrolled in their BASILICA trial, with the use of a cerebral embolic protection device in merely one of them [9]. However, in the large cohort described above embolic protection was not associated with differences in stroke rate [20]. Therefore, specific impact of BASILICA on the risk of stroke during TAVI remains uncertain until larger investigative series are available. Until then, we would advocate for a liberal use of embolic protection devices for this complex subset of patients.

**Transesophageal echocardiography guidance**

Optimal intra-procedural visualization with delineation of critical cardiac structures is crucial for a safe and successful BASILICA procedure. Utilization of both fluoroscopic
front and side view projections of the target cusp enabling to implement of precise leaflet traversal site and direction is recommended by its pioneering experts [6]. However, the feasibility of achieving fluoroscopic projections pre-determined by MSCT before the procedure in a standard catheter laboratory is limited in most cases [21]. In particular, LCC front view and RCC side view projections can be challenging to obtain or are unachievable. Thus, the usage of modified projections not perfectly anatomically aligned or repositioning of the patient on C-arm table has been proposed. Transesophageal echocardiography allows for a visualization of the key steps and structures, including LCA and RCA ostia, during the entire leaflet traversal scenario. This can be helpful since coronary ostia occasionally have an eccentric origin in relation to the center of the target cusp affecting the target point for leaflet traversal and laceration [22]. Therefore, we decided to use intra-procedural transesophageal echocardiography as an additional and important guidance-imaging tool to facilitate and shorten the procedure. This is currently also recommended by others [23]. Certainly, implementation by an experienced echocardiographer is mandatory for safe and reliable echocardiographic guiding and validation of the BASILICA procedure.

Limitations

This study is limited by its study design and small sample size, and may, therefore, only serve to generate hypotheses. However, the presented results with this novel technique are in line with previous studies of comparable sample sizes and support the broader use of this procedure in patients at risk. The results of the prospective BASILICA trial (NCT03381989) are highly awaited and will shed more light on outcomes of patients at high risk for coronary obstruction undergoing native valve TAVI or ViV TAVI.

Conclusions

The results of our present single-center study support the use of the BASILICA technique as a safe and effective preventive treatment option in patients at high or prohibitive risk of iatrogenic coronary obstruction during native valve TAVI and ViV TAVI. The procedure was performed successfully in the majority of patients with absence or low rates of VARC-2 defined peri- and post-procedural complications.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s00392-021-01881-4.

Funding  Open Access funding enabled and organized by Projekt DEAL. The authors did not receive specific funding for the conduct of this study.

Declarations

Conflict of interest  DW reports personal fees from AstraZeneca, Bayer, Berlin-Chemie and Novartis. JL reports non-financial support from Edwards Lifesciences. DK has received lecture fees and travel support from Abbott and lecture as well as proctor fees and travel support from Edwards Lifesciences. MS reports non-financial support from Abbott, Biotronik, Boehringer Ingelheim, Boston Scientific, Edwards Lifesciences, Nicolai Medizintechnik, OrbusNeich Medical, personal fees from Abiomed, Amgen, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, Boston Scientific, Medtronic, Philips and Shockwave Medical and grants from Philips. NS reports personal fees from Boston Scientific and non-financial support from Abbott and Edwards Lifesciences. SB reports grants and personal fees from Abbott, Bayer and Thermo Fisher, grants from SIEMENS and Singulex, personal fees from Abbott, Astra Zeneca AMIGEN, Medtronic, Pfizer, Roche, Novartis and Siemens Diagnostics. LC is proctor and consultant for Edwards Lifesciences and Boston Scientific and consultant for Medtronic and Abbott Vascular. JS reports lecture fees from Edwards Lifesciences, travel compensation from Boston Scientific and Edwards Lifesciences and is a proctor for Symetis SA and JenaValve. All other authors report no conflicts of interest.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Reinöhl J, Kaier K, Reinecke H et al (2015) Effect of availability of transcatheter aortic-valve replacement on clinical practice. N Engl J Med. https://doi.org/10.1056/NEJMa1500893
2. Ribeiro HB, Rodés-Cabau J, Blanke P et al (2018) Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. Eur Heart J 39:687–695. https://doi.org/10.1093/eurheartj/ehx455
3. Arai T, Lefèvre T, Hovasse T et al (2017) Incidence and predictors of coronary obstruction following transcatheter aortic valve implantation in the real world. Catheter Cardiovasc Interv 90:1192–1197. https://doi.org/10.1002/ccd.26982
4. Ribeiro HB, Webb JG, Makkar RR et al (2013) Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 62:1552–1562. https://doi.org/10.1016/j.jcc.2013.07.040
5. Danny D, John W, Stephen B et al (2012) Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves. Circulation 126:2335–2344. https://doi.org/10.1161/CIRCULATIONAHA.112.104505
6. Lederman RJ, Babalioss VC, Rogers T et al (2019) Preventing coronary obstruction during transcatheter aortic valve replacement: from computed tomography to BASILICA. JACC Cardiovasc Interv 12(13):1197–1216
7. Mercanti F, Rosseel L, Neylon A et al (2020) Chimney stenting for coronary occlusion during TAVR: insights from the Chimney Registry. JACC Cardiovasc Interv 13:751–761. https://doi.org/10.1016/j.jcin.2020.01.227
8. Khan JM, Dvir D, Greenbaum AB et al (2018) Transcatheter laceration of aortic leaflets to prevent coronary obstruction during transcatheter aortic valve replacement: concept to first-in-human. JACC Cardiovasc Interv. https://doi.org/10.1016/j.jcin.2018.01.247
9. Khan JM, Greenbaum AB, Babaliaros VC et al (2019) The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv. https://doi.org/10.1016/j.jcin.2019.03.035
10. Kitamura M, Majunke N, Holzhey D et al (2020) Systematic use of intentional leaflet laceration to prevent TAVI-induced coronary obstruction: feasibility and early clinical outcomes of the BASILICA technique. EuroIntervention. https://doi.org/10.4244/EIJ-D-20-00386
11. Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. https://doi.org/10.1093/eurheartj/ehx391
12. Kasel AM, Cassese S, Bleiziffer S et al (2013) Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. JACC Cardiovasc Imaging 6:249–262. https://doi.org/10.1016/j.jcmg.2012.12.005
13. Blanke P, Soon J, Dvir D et al (2016) Computed tomography assessment for transcatheter aortic valve in valve implantation: the Vancouver approach to predict anatomical risk for coronary obstruction and other considerations. J Cardiovasc Comput Tomogr 10:491–499. https://doi.org/10.1016/j.jcct.2016.09.004
14. Dvir D, Khan J, Kornowski R et al (2018) Novel strategies in aortic valve-in-valve therapy including bioprosthetic valve fracture and BASILICA. EuroIntervention. https://doi.org/10.4244/eij-d-18-00667
15. Ribeiro HB, Nombela-Franco L, Urena M et al (2013) Coronary obstruction following transcatheter aortic valve implantation: a systematic review. JACC Cardiovasc Interv 6:452–461. https://doi.org/10.1016/j.jcin.2012.11.014
16. Seipelt RG, Hanekop G-G, Schoendube FA, Schillinger W (2012) Heart team approach for transcatheter aortic valve implantation procedures complicated by coronary artery occlusion. Interact Cardiovasc Thorac Surg 14:431–433. https://doi.org/10.1093/icvts/ivr136
17. Bernardi FLM, Dvir D, Rodes-Cabau J, Ribeiro HB (2019) Valve-in-valve challenges: how to avoid coronary obstruction. Front Cardiovasc Med 6:120
18. Dvir D, Leipsic J, Blanke P et al (2015) Coronary obstruction in transcatheter aortic valve-in-valve implantation preprocedural evaluation, device selection, protection, and treatment. Circ Cardiovasc Interv 8(1):e002079
19. Tang GHL, Komatsu I, Tzemach L et al (2020) (9AD) Risk of coronary obstruction and the need to perform BASILICA: the VIVID classification. EuroIntervention 16:e757–e759
20. Khan JM, Babaliaros VC, Greenbaum AB et al (2021) Preventing coronary obstruction during transcatheter aortic valve replacement: results from the Multicenter International BASILICA Registry. JACC Cardiovasc Interv. https://doi.org/10.1016/j.jcin.2021.02.035
21. Komatsu I, Tang G, Leipsic J et al (2020) Distribution of C-arm projections in native and bioprosthetic aortic valves cusps: implication for BASILICA procedures. Catheter Cardiovasc Interv. https://doi.org/10.1002/ccd.29224
22. Komatsu I, Leipsic J, Webb JG et al (2020) Coronary ostial eccentricity in severe aortic stenosis: guidance for BASILICA transcatheter leaflet laceration. J Cardiovasc Comput Tomogr 14:516–519. https://doi.org/10.1016/j.jcct.2020.02.006
23. Protsyk V, Meineri M, Kitamura M et al (2021) Echocardiographic guidance of intentional leaflet laceration prior to transcatheter aortic valve replacement: a structured approach to the BASILICA procedure. J Am Soc Echocardiogr. https://doi.org/10.1016/j.echo.2021.01.015